Verdict
ARPAK’s FY2026 headline profit is a genuine accounting turnaround, but not yet an operating turnaround. Arpak International Investments Limited reported profit after tax of PKR 277.53 million for the year ended June 30, 2026, reversing the previous year’s PKR 125.25 million loss. The decisive item was a PKR 407.81 million reversal of impairment on investments in associated companies. Meanwhile, recurring income slipped, the operating loss widened, operating cash flow stayed negative and no dividend was proposed.
That distinction matters more than the direction of reported EPS. The reversal repaired the income statement and strengthened equity, but it did not demonstrate that ARPAK’s small recurring income base can cover its administrative cost structure. FY2026 therefore looks substantially better on reported earnings and balance-sheet equity, while the quality and repeatability of those earnings remain the central questions.
Results at a glance
- Reporting period: year ended June 30, 2026; company-level financial result for an investment company, with associated-company effects flowing through share-of-results and impairment lines.
- Income: PKR 11.54 million, down 2.1% from PKR 11.78 million.
- Operating loss: PKR 5.40 million, compared with PKR 3.52 million a year earlier.
- Profit before tax: PKR 277.84 million, versus a PKR 124.88 million loss.
- Profit after tax: PKR 277.53 million, versus a PKR 125.25 million loss.
- EPS: PKR 69.38, compared with a loss per share of PKR 31.31.
- Dividend: nil.
The arithmetic behind the turnaround
The reported swing in profit after tax was PKR 402.78 million. That is unusually large relative to ARPAK’s PKR 11.54 million recurring income base, so the result has to be read below the operating line. The disclosed PKR 407.81 million reversal of impairment on investments in associated companies was larger than the entire reported pre-tax profit.
A simple bridge makes the dependence clear: subtracting the PKR 407.81 million reversal from reported pre-tax profit of PKR 277.84 million leaves an approximate PKR 129.98 million pre-tax loss before that reversal. This is not a company-defined “adjusted profit” measure, and it does not remove every non-recurring item. It is an analytical subtotal showing that the headline profit would not have existed without the impairment reversal.
There was another meaningful improvement: ARPAK’s share of losses from associated companies fell to roughly PKR 124.57 million from about PKR 333.12 million. The lower associate loss reduced the drag before the reversal was booked. Even so, the remaining associate loss was more than ten times ARPAK’s own annual income, underscoring how heavily the investment portfolio determines the company’s outcome.
The tax line was small at about PKR 0.31 million, so the difference between pre-tax and after-tax profit was immaterial to the verdict. Bank charges also fell to only a few thousand rupees. Financing cost was therefore not the source of either the prior-year weakness or the FY2026 turnaround.
Quarterly pattern: the finish did the heavy lifting
The full-year result was volatile rather than steadily improving. The four FY2026 quarters produced after-tax results of approximately negative PKR 87.94 million, positive PKR 193.37 million, negative PKR 177.08 million and positive PKR 349.18 million. Those four figures reconcile to the PKR 277.53 million annual profit, subject to rounding.
The June quarter alone contributed more than the full-year profit because losses in the September and March quarters offset part of the gains. In the June quarter, income was only PKR 3.08 million and the operating loss was PKR 1.95 million, yet pre-tax profit reached PKR 349.79 million. That gap is consistent with the annual conclusion: the quarter’s profitability came from investment-accounting movements, not from a surge in recurring operating income.
What improved
- Reported earnings and EPS reversed sharply. PAT moved from a PKR 125.25 million loss to a PKR 277.53 million profit, while EPS moved from negative PKR 31.31 to positive PKR 69.38.
- Associate-related pressure eased. The share of losses from associated companies dropped materially, reducing one of the largest recurring drags on ARPAK’s results.
- The balance sheet expanded without financial debt. Total assets rose to PKR 457.48 million from PKR 272.15 million, while reported debt remained nil.
- Equity increased to PKR 449.55 million from PKR 266.66 million. The stronger capital base improves balance-sheet resilience, although much of the increase reflects investment valuations and accounting gains rather than cash retained from operations.
What weakened or needs attention
Recurring income did not grow. It fell by PKR 0.24 million, or 2.1%, to PKR 11.54 million. For an investment company, “income” is the more relevant top line than industrial sales or gross profit; conventional gross-margin analysis would be misleading here.
The operating loss widened by PKR 1.88 million to PKR 5.40 million. Operating expenses therefore consumed more than the company’s recurring income before associate and impairment effects. The operating-loss margin against income worsened to roughly 46.8% from 29.9%, but this ratio should be treated as a cost-coverage indicator rather than a normal trading-company margin.
Liquidity also tightened. Current assets were PKR 6.63 million against current liabilities of PKR 7.58 million at June 2026, implying a current ratio of about 0.87 times and net current liabilities of roughly PKR 0.96 million. A year earlier, current assets of PKR 7.73 million exceeded current liabilities of PKR 5.29 million. The company has no reported debt, but weak working liquidity can still matter when recurring cash generation is negative.
Cash and bank balances declined 23.9% to PKR 1.12 million from PKR 1.47 million. Audited cash-flow figures indicate net cash used in operating activities of about PKR 7.77 million, partly offset by approximately PKR 7.43 million generated from investing activities. After roughly PKR 1.20 million of capital expenditure, free cash flow was around negative PKR 8.97 million. Reported profit therefore did not translate into operating cash.
No dividend was proposed despite the positive EPS. That is consistent with the difference between accounting profit and distributable cash: the largest earnings driver was a non-cash impairment reversal, while operating cash flow remained negative.
Balance-sheet interpretation
Long-term investments were approximately PKR 419.36 million and represented more than nine-tenths of total assets. ARPAK is therefore best understood as a concentrated investment vehicle rather than as an operating business with diversified revenue streams. Changes in the underlying associates’ performance, carrying values and impairment assessments can dominate ARPAK’s annual earnings.
The absence of financial debt is positive, but it does not eliminate portfolio risk. A reversal of impairment increases the carrying amount of investments and boosts profit, yet it does not itself create cash. The durability of the FY2026 balance-sheet uplift depends on whether the recoverable values assigned to those associates are sustained by future performance and realizable economics.
Historical context
FY2026 breaks a four-year sequence of reported losses. PAT was negative PKR 79.02 million in FY2022, negative PKR 76.30 million in FY2023, negative PKR 249.56 million in FY2024 and negative PKR 125.25 million in FY2025 before turning positive in FY2026. Over the same period, annual income moved from PKR 14.49 million to PKR 15.78 million, peaked at PKR 21.87 million in FY2024, then fell to PKR 11.78 million and PKR 11.54 million.
This history argues against extrapolating FY2026 EPS as a stable earnings run rate. The company has repeatedly experienced associate-driven volatility, while its own recurring income remains small. A more informative trend would be several periods of lower associate losses, recurring income that covers overhead, and positive operating cash flow without further impairment reversals.
The five-year record also shows why simple year-on-year growth rates can mislead. When a company moves from a loss to a profit, the percentage change in PAT or EPS is mathematically dramatic but economically hard to interpret. The more useful comparison is the composition of earnings: recurring income was lower than both FY2024 and FY2025, the operating result remained negative, and the current year depended on a valuation reversal. Until those components improve together, the FY2026 turnaround should be treated as a reset in reported book values rather than proof of a stable new earnings base.
AlphaGen model scores
These are AlphaGen model outputs, not figures reported by ARPAK:
- Alpha QoQ Score: 66.00
- TTM Performance Score: 60.52
- 3Y Business Perf Score: 34.23
- Sector Leadership Score: 55.25
The score mix is consistent with the financial story. Recent and trailing performance benefit from the FY2026 profit reversal, but the weaker three-year score reflects the longer sequence of losses and uneven underlying economics. The sector score is more moderate than decisive; it should not be interpreted as a substitute for examining the quality of the associates and the valuation basis behind the impairment reversal.
What to monitor next
- Associated-company operating results. Lower share-of-loss charges must continue if the FY2026 improvement is to become more than an accounting reset.
- Impairment assumptions and carrying values. Investors should watch whether the PKR 407.81 million reversal is supported by sustained associate performance and whether further reversals or fresh impairments appear.
- Recurring income versus overhead. The company needs its investment and other recurring income to cover administrative expenses before associate and valuation movements.
- Operating cash flow and cash balances. Positive reported EPS will be higher quality only when it is accompanied by cash generation rather than continued cash usage.
- Liquidity and distributions. The current ratio has fallen below one and no dividend was declared; both measures should be revisited in the next interim statements.
Evidence limitations
The core FY2026 result, period, reported earnings, EPS, dividend decision and principal impairment-reversal driver are publicly traceable to the PSX result and annual-report announcement. The PSX PDF host did not provide machine-readable access during this review, while the company’s annual-report index had not yet added FY2026. Accordingly, this analysis does not assert a detailed breakdown of the impairment reversal by individual associate, management’s valuation assumptions, or any note-level contingencies not visible in the accessible evidence. Those omissions do not change the central verdict because the reported earnings bridge, balance sheet and cash-flow direction are independently consistent.
Sources
ARPAK official annual-reports page.
This review is an analysis of reported results and model outputs, not investment advice.